{"id":"bevacizumab-and-folfiri","safety":{"commonSideEffects":[{"rate":"null","effect":"Hypertension"},{"rate":"null","effect":"Diarrhea"},{"rate":"null","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1201583","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bevacizumab works by binding to VEGF-A, preventing it from interacting with its receptor and thus inhibiting the formation of new blood vessels that tumors need to grow. FOLFIRI, on the other hand, targets rapidly dividing cancer cells by inhibiting topoisomerase I, an enzyme involved in DNA replication.","oneSentence":"Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), while FOLFIRI is a chemotherapy regimen that includes irinotecan, a topoisomerase I inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:23:08.526Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT07221357","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-12-31","conditions":"Untreated, Unresectable, or Metastatic Colorectal Cancer","enrollment":990},{"nctId":"NCT06252649","phase":"PHASE3","title":"Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-07-17","conditions":"Metastatic Colorectal Cancer","enrollment":450},{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT05863195","phase":"PHASE3","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-10-19","conditions":"Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8","enrollment":408},{"nctId":"NCT06663319","phase":"PHASE1","title":"A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-15","conditions":"Colorectal Neoplasms, Gastrointestinal Neoplasms","enrollment":220},{"nctId":"NCT06011772","phase":"EARLY_PHASE1","title":"EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2023-12-18","conditions":"Colo-rectal Cancer","enrollment":2},{"nctId":"NCT05239741","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-04-02","conditions":"Colorectal Neoplasms","enrollment":100},{"nctId":"NCT07446322","phase":"PHASE2","title":"FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Oncolytics Biotech","startDate":"2026-04-30","conditions":"Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer","enrollment":60},{"nctId":"NCT04929223","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-22","conditions":"Metastatic Colorectal Cancer","enrollment":542},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT05083481","phase":"PHASE1, PHASE2","title":"A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-10-19","conditions":"Advanced Solid Tumors","enrollment":366},{"nctId":"NCT07193862","phase":"EARLY_PHASE1","title":"Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2025-12-10","conditions":"Colorectal Cancer Metastatic","enrollment":10},{"nctId":"NCT07318389","phase":"EARLY_PHASE1","title":"ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-06-10","conditions":"Dynamic Tumor Resistance, Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT05983367","phase":"PHASE2","title":"A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Inspirna, Inc.","startDate":"2023-10-10","conditions":"Colorectal Cancer, Metastatic Colon Cancer","enrollment":76},{"nctId":"NCT04485013","phase":"PHASE1","title":"TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers","status":"RECRUITING","sponsor":"Tizona Therapeutics, Inc","startDate":"2020-07-14","conditions":"Cancer","enrollment":240},{"nctId":"NCT06750094","phase":"PHASE3","title":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-12","conditions":"Colorectal Neoplasms","enrollment":700},{"nctId":"NCT06728072","phase":"PHASE2","title":"Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2025-03-07","conditions":"Colorectal Cancer, CRC","enrollment":97},{"nctId":"NCT07323576","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2026-02-01","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT07391566","phase":"PHASE1, PHASE2","title":"LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation","status":"NOT_YET_RECRUITING","sponsor":"Luye Pharma Group Ltd.","startDate":"2026-03-31","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":99},{"nctId":"NCT07391618","phase":"PHASE2","title":"Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-05-15","conditions":"Advanced Colorectal Cancer","enrollment":583},{"nctId":"NCT05062317","phase":"PHASE2","title":"ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-04-26","conditions":"Liver Metastases","enrollment":120},{"nctId":"NCT07389265","phase":"PHASE3","title":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2025-10-01","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":480},{"nctId":"NCT04587128","phase":"PHASE2","title":"Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2020-10-19","conditions":"Metastatic Colorectal Cancer","enrollment":34},{"nctId":"NCT06771622","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"FBD Biologics Limited","startDate":"2025-03-13","conditions":"Solid Cancer","enrollment":500},{"nctId":"NCT03798626","phase":"PHASE1","title":"Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-22","conditions":"Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma","enrollment":167},{"nctId":"NCT07359456","phase":"PHASE2","title":"Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-03","conditions":"Metastatic Colorectal Cancer","enrollment":130},{"nctId":"NCT07355764","phase":"PHASE2","title":"MA-CRC-II-016 SHR-1811","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-12-30","conditions":"mCRC, HER2, Targeted Therapy","enrollment":80},{"nctId":"NCT06792695","phase":"PHASE2","title":"A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-12","conditions":"Metastatic Colorectal Cancer","enrollment":120},{"nctId":"NCT07094893","phase":"PHASE4","title":"Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2026-04-15","conditions":"Colorectal Cancer","enrollment":280},{"nctId":"NCT07337551","phase":"PHASE2","title":"Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive","status":"NOT_YET_RECRUITING","sponsor":"Guiying Wang","startDate":"2026-02-01","conditions":"Patients With Metastatic Colorectal Cancer Who Were TP53-mutant and LRPPRC-positive and Had Previously Failed Prior First-line Treatment","enrollment":20},{"nctId":"NCT06106308","phase":"PHASE2","title":"Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cardiff Oncology","startDate":"2024-02-27","conditions":"Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation","enrollment":113},{"nctId":"NCT06838338","phase":"PHASE1","title":"JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jian Li","startDate":"2025-03-20","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT06332079","phase":"PHASE2","title":"Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients","status":"TERMINATED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-03-13","conditions":"Colorectal Cancer Metastatic","enrollment":4},{"nctId":"NCT07079462","phase":"PHASE2","title":"Comparing 68Ga-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-01","conditions":"Colorectal Cancer, Peritoneal (Metastatic) Cancer, FAPI PET","enrollment":40},{"nctId":"NCT05836324","phase":"PHASE1","title":"A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2023-07-24","conditions":"Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":408},{"nctId":"NCT06509906","phase":"PHASE1","title":"M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2024-10-08","conditions":"Advanced Solid Tumor","enrollment":3},{"nctId":"NCT07271355","phase":"PHASE3","title":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-07-01","conditions":"Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum","enrollment":129},{"nctId":"NCT05843188","phase":"PHASE2","title":"Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-08-09","conditions":"Metastatic Colorectal Cancer","enrollment":155},{"nctId":"NCT07253896","phase":"PHASE2","title":"Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-01-03","conditions":"Safety","enrollment":40},{"nctId":"NCT07204574","phase":"PHASE1, PHASE2","title":"The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-05-14","conditions":"CRC","enrollment":40},{"nctId":"NCT04776655","phase":"PHASE3","title":"Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB","status":"RECRUITING","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2021-04-30","conditions":"Colorectal Cancer, Metastatic Colorectal Cancer, RAS Mutation","enrollment":280},{"nctId":"NCT07150247","phase":"PHASE2","title":"Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-06-01","conditions":"BRAF V600 Colorectal Cancer","enrollment":20},{"nctId":"NCT05678257","phase":"PHASE2","title":"A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer","status":"TERMINATED","sponsor":"NuCana plc","startDate":"2023-04-18","conditions":"Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma","enrollment":180},{"nctId":"NCT07150403","phase":"PHASE2","title":"Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2025-12-31","conditions":"Metastatic Colorectal Carcinoma (mCRC)","enrollment":74},{"nctId":"NCT06936527","phase":"PHASE1, PHASE2","title":"XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation","status":"ENROLLING_BY_INVITATION","sponsor":"NovaOnco Therapeutics Co., Ltd.","startDate":"2025-05-23","conditions":"Colorectal Cancer, Metastatic Colorectal Cancer With RAS Mutation","enrollment":102},{"nctId":"NCT06867822","phase":"PHASE1","title":"Trial of ProAgio in Advanced/Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-07-17","conditions":"Advanced Colorectal Cancer, Metastatic Colorectal Cancer","enrollment":27},{"nctId":"NCT07106034","phase":"PHASE2","title":"Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pudong Hospital","startDate":"2025-08-31","conditions":"Advanced Colorectal Cancer","enrollment":32},{"nctId":"NCT06856187","phase":"PHASE2","title":"Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-28","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":119},{"nctId":"NCT05480306","phase":"PHASE2","title":"Phase 2 Study of DKN-01 in Colorectal Cancer","status":"COMPLETED","sponsor":"Leap Therapeutics, Inc.","startDate":"2022-08-30","conditions":"Colorectal Cancer, Colorectal Adenocarcinoma, Colo-rectal Cancer","enrollment":188},{"nctId":"NCT03872947","phase":"PHASE1","title":"A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Toray Industries, Inc","startDate":"2019-04-26","conditions":"Solid Tumor, Colorectal Cancer, Cholangiocarcinoma","enrollment":138},{"nctId":"NCT05330429","phase":"PHASE2","title":"Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2022-07-08","conditions":"Metastatic Colorectal Cancer","enrollment":77},{"nctId":"NCT03186326","phase":"PHASE2","title":"Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-04-24","conditions":"Metastatic Colorectal Cancer, MSI","enrollment":132},{"nctId":"NCT07021950","phase":"PHASE2","title":"AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-10","conditions":"Colorectal Cancer, Ivonescimab","enrollment":130},{"nctId":"NCT05312398","phase":"PHASE2","title":"CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2021-07-15","conditions":"Metastatic Colorectal Adenocarcinoma","enrollment":219},{"nctId":"NCT02138617","phase":"PHASE2","title":"Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2014-05-06","conditions":"Colon Cancer","enrollment":100},{"nctId":"NCT05848739","phase":"PHASE1","title":"A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Sapience Therapeutics","startDate":"2023-06-05","conditions":"Colon Cancer, Metastatic Colon Cancer","enrollment":130},{"nctId":"NCT02934529","phase":"PHASE3","title":"Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2015-03","conditions":"Metastatic Colorectal Cancer","enrollment":673},{"nctId":"NCT03597581","phase":"PHASE1","title":"A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Inspirna, Inc.","startDate":"2018-06-05","conditions":"Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer","enrollment":89},{"nctId":"NCT04553692","phase":"PHASE1","title":"Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers","status":"TERMINATED","sponsor":"IGM Biosciences, Inc.","startDate":"2020-09-23","conditions":"Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma","enrollment":272},{"nctId":"NCT04952753","phase":"PHASE2","title":"Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-11-15","conditions":"Metastatic Colorectal Cancer","enrollment":204},{"nctId":"NCT06857773","phase":"PHASE3","title":"Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-11-21","conditions":"Colorectal Neoplasms, Floxuridine, Liver Metastases","enrollment":306},{"nctId":"NCT03829410","phase":"PHASE1, PHASE2","title":"Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation","status":"COMPLETED","sponsor":"Cardiff Oncology","startDate":"2019-06-24","conditions":"Metastatic Colorectal Cancer, KRAS Gene Mutation","enrollment":68},{"nctId":"NCT06843954","phase":"PHASE4","title":"Impact of Vascular Endothelial Growth Factor Gene Polymorphisms on Bevacizumab Efficacy in a Sample of Iraqi Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Mohammed Mahmood Mohammed","startDate":"2022-09-01","conditions":"Colo-rectal Cancer","enrollment":157},{"nctId":"NCT06841159","phase":"PHASE2","title":"Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-01","conditions":"Microsatellite Stable Metastatic Colorectal Cancer","enrollment":116},{"nctId":"NCT05087992","phase":"PHASE1","title":"A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-11-24","conditions":"Gastrointestinal Cancer, Metastatic","enrollment":13},{"nctId":"NCT02162563","phase":"PHASE3","title":"Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases","status":"COMPLETED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2014-07","conditions":"Colorectal Cancer, Liver Metastases","enrollment":530},{"nctId":"NCT03117972","phase":"PHASE2","title":"Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2017-08-04","conditions":"Metastatic Colorectal Cancer","enrollment":54},{"nctId":"NCT01814501","phase":"PHASE2","title":"Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab","status":"COMPLETED","sponsor":"John Hays","startDate":"2013-02-01","conditions":"Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer","enrollment":16},{"nctId":"NCT01878422","phase":"PHASE3","title":"Sequential Treatment Strategy for Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2007-11","conditions":"Metastatic Colorectal Cancer","enrollment":376},{"nctId":"NCT05593328","phase":"PHASE2","title":"Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation","status":"COMPLETED","sponsor":"Cardiff Oncology","startDate":"2023-03-17","conditions":"Colorectal Cancer, Metastatic Colorectal Cancer","enrollment":23},{"nctId":"NCT01167725","phase":"PHASE3","title":"Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-08","conditions":"Colorectal Cancer","enrollment":340},{"nctId":"NCT06139211","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2024-01-03","conditions":"Advanced Solid Tumor","enrollment":186},{"nctId":"NCT05462613","phase":"PHASE2, PHASE3","title":"Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2023-05-09","conditions":"Metastatic Colorectal Cancer","enrollment":446},{"nctId":"NCT05969899","phase":"PHASE2","title":"Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2023-07-10","conditions":"Colorectal Cancer","enrollment":50},{"nctId":"NCT03635021","phase":"PHASE3","title":"Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2018-10-15","conditions":"Colorectal Cancer","enrollment":419},{"nctId":"NCT02563002","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-30","conditions":"Colorectal Carcinoma","enrollment":307},{"nctId":"NCT03164655","phase":"PHASE2","title":"Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2018-07-25","conditions":"Colorectal Cancer Metastatic","enrollment":20},{"nctId":"NCT05628038","phase":"PHASE2","title":"The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-30","conditions":"Recurrent Rectal Cancer","enrollment":93},{"nctId":"NCT06590259","phase":"PHASE2","title":"A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM","status":"RECRUITING","sponsor":"Shanghai 6th People's Hospital","startDate":"2024-03-12","conditions":"Colorectal Cancer Liver Metastasis","enrollment":20},{"nctId":"NCT06603376","phase":"PHASE2","title":"Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2024-09-01","conditions":"Colorectal Carcinoma","enrollment":75},{"nctId":"NCT06525428","phase":"PHASE2","title":"Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04-01","conditions":"Microsatellite Stable Metastatic Colorectal Cancer","enrollment":96},{"nctId":"NCT05039944","phase":"PHASE2","title":"SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies","status":"TERMINATED","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2021-11-30","conditions":"Colorectal Cancer","enrollment":7},{"nctId":"NCT02842580","phase":"PHASE2","title":"De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2016-09","conditions":"Colorectal Neoplasms","enrollment":21},{"nctId":"NCT06447727","phase":"","title":"Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM","status":"RECRUITING","sponsor":"Zhongda Hospital","startDate":"2024-05-20","conditions":"Colorectal Cancer Metastatic","enrollment":30},{"nctId":"NCT03250832","phase":"PHASE1","title":"Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-08-08","conditions":"Neoplasms","enrollment":111},{"nctId":"NCT01910610","phase":"PHASE3","title":"Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2013-10-30","conditions":"Colorectal Cancer Metastatic","enrollment":464},{"nctId":"NCT06293014","phase":"PHASE2","title":"TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-02-23","conditions":"Colorectal Cancer","enrollment":224},{"nctId":"NCT06269445","phase":"PHASE4","title":"The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal Cancer","status":"UNKNOWN","sponsor":"Sir Run Run Shaw Hospital","startDate":"2024-01-01","conditions":"Colorectal Cancer","enrollment":20},{"nctId":"NCT04446793","phase":"","title":"Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer","status":"NO_LONGER_AVAILABLE","sponsor":"Cardiff Oncology","startDate":"","conditions":"Metastatic Colorectal Cancer, KRAS Gene Mutation","enrollment":""},{"nctId":"NCT03135652","phase":"PHASE2","title":"Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation","status":"WITHDRAWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2017-08-01","conditions":"Radiotherapy, Colorectal Cancer, Liver Metastases","enrollment":""},{"nctId":"NCT06176885","phase":"PHASE2","title":"Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"yue junhan","startDate":"2023-12-20","conditions":"Colorectal Cancer","enrollment":36},{"nctId":"NCT05631041","phase":"PHASE3","title":"Effect of Silymarin in Metastatic Colorectal Cancer Patients","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-12-31","conditions":"Metastatic Colorectal Cancer","enrollment":64},{"nctId":"NCT02024607","phase":"PHASE1, PHASE2","title":"A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2014-01","conditions":"Advanced Gastrointestinal Cancer","enrollment":495},{"nctId":"NCT02753127","phase":"PHASE3","title":"A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2016-06","conditions":"Colorectal Cancer","enrollment":1253},{"nctId":"NCT04299880","phase":"PHASE1","title":"Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2020-02-24","conditions":"Oncology","enrollment":7},{"nctId":"NCT01133990","phase":"PHASE1, PHASE2","title":"FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2010-03-04","conditions":"Colorectal Cancer","enrollment":5},{"nctId":"NCT05862051","phase":"NA","title":"RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-12-14","conditions":"Colorectal Cancer, Oligometastatic Disease","enrollment":75},{"nctId":"NCT01606098","phase":"PHASE3","title":"The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer","status":"COMPLETED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2012-07","conditions":"Colon Cancer, Primary Tumour, Rectal Cancer","enrollment":206},{"nctId":"NCT05555901","phase":"PHASE2","title":"The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2023-06-18","conditions":"Metastatic Colorectal Cancer","enrollment":116},{"nctId":"NCT03743428","phase":"NA","title":"Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C)","status":"SUSPENDED","sponsor":"Shenzhen People's Hospital","startDate":"2020-10-22","conditions":"Colorectal Neoplasms","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":109,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CPT11","Folinic acid","5FU"],"phase":"phase_2","status":"active","brandName":"Bevacizumab and FOLFIRI","genericName":"Bevacizumab and FOLFIRI","companyName":"Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente","companyId":"gruppo-italiano-per-lo-studio-dei-carcinomi-dell-apparato-digerente","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), while FOLFIRI is a chemotherapy regimen that includes irinotecan, a topoisomerase I inhibitor. Used for Metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}